Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetirizine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cetirizine HCl Tablets 10 mg |
| 2 | ACTIVE_COMPARATOR | Zyrtec® 10 mg |
| Name | Type | Description |
|---|---|---|
| Cetirizine HCl Tablets 10 mg | DRUG | 10mg, single dose fed |
| Zyrtec® 10 mg | DRUG | 10mg, single dose fed |
| Zyrtec® Tablets 10 mg | DRUG | 10mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...
Cetirizine is a small molecule drug developed by Viatris Inc., which trades under the ticker VTRS. It is also known as Cetirizine HCl Tablets 10 mg. The drug is in Phase 1 clinical development, and its studied indications are undisclosed.
Cetirizine targets HRH1, the histamine H1 receptor. It acts as an antagonist at this receptor. This target class places Cetirizine among histamine H1 receptor antagonists, which is the mechanism described for this small molecule asset.
Cetirizine is developed by Viatris Inc., a company that trades on the stock market under the ticker symbol VTRS. Viatris is the sponsor associated with the clinical trials of Cetirizine HCl Tablets 10 mg.
Cetirizine is in Phase 1 clinical development. It is an investigational drug and is not approved. Two Phase 1 trials of Cetirizine have been completed, and no trials are currently active.
Two completed Phase 1 trials have studied Cetirizine. NCT00650065 was a fasting study comparing Cetirizine HCl Tablets 10 mg with Zyrtec tablets 10 mg in 26 healthy volunteers. NCT00649857 was a food study of the same comparison in 18 healthy volunteers. Both enrolled adults in the United States.